| (210) | Number of the EPO application | 17726862 |
| (220) | Filing date of the EPO application | 2017.05.17 |
| (80) | EPO patent specification publication (B) | EPB nr. 01/2021, 2021.01.06 |
| (110) | EPO patent number | 3458478 |
| (21) | Number of the application | e 2019 0359 |
| (71) | Name(s) of applicant(s), code of the country | Boehringer Ingelheim International GmbH, DE; |
| (72) | Name(s) of inventor(s), code of the country | ZETTL Markus, DE;
LORENZ Ivo, US;
SCHAAF Otmar, DE;
WURM Melanie, DE;
FORTIN Jean-François, CA;
BRODEUR Scott, US;
CANADA Keith A., US;
CHLEWICKI Lukasz, US;
GUPTA Pankaj, US;
GUPTA Priyanka, US;
PEREZ Rocio K., US;
WOSKA Jr. Joseph Robert, US;
XIAO Haiguang, US;
YANG Danlin, US;
DAVIDSON Walter Carroll, US; |
| (73) | Name(s) of owner(s), code of the country | BOEHRINGER Ingelheim International GmbH, DE; |
| (54) | Title of the invention | ANTI PD-1 AND ANTI-LAG3 ANTIBODIES FOR CANCER TREATMENT |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | C07K 16/28 (2006.01.01); A61K 39/00 (2006.01.01) |
| (19) | Country | DE |
| (41) | Date of publication of the application | 2019.04.30 |
| (30) | Priority | 16170174, 2016.05.18, EP |
| (86) | International application | PCT/EP2017/061901, 2017.05.17 |
| (87) | International publication | WO 2017/198741, 2017.11.23 |